ClearPoint Neuro, Inc. (CLPT) |
| 10.01 1.33 (15.32%) 04-13 16:00 |
| Open: | 8.7 |
| High: | 10.01 |
| Low: | 8.64 |
| Volume: | 725,687 |
| Market Cap: | 298(M) |
| PE Ratio: | -11.12 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 11.90 |
| Resistance 1: | 10.51 |
| Pivot price: | 9.23 |
| Support 1: | 8.27 |
| Support 2: | 6.88 |
| 52w High: | 30.1 |
| 52w Low: | 8.27 |
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
| EPS | -0.900 |
| Book Value | 0.950 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.765 |
| Profit Margin (%) | -69.08 |
| Operating Margin (%) | -50.38 |
| Return on Assets (ttm) | -20.4 |
| Return on Equity (ttm) | -95.6 |
Fri, 10 Apr 2026
ClearPoint Neuro (NASDAQ: CLPT) seeks approval for larger equity incentive plan - Stock Titan
Fri, 10 Apr 2026
CLPT Stock Price, Quote & Chart | CLEARPOINT NEURO INC (NASDAQ:CLPT) - ChartMill
Tue, 07 Apr 2026
ClearPoint Neuro (CLPT) price target decreased by 10.71% to 25.50 - MSN
Mon, 06 Apr 2026
Why The ClearPoint Neuro (CLPT) Investment Story Is Shifting On Regulatory And Partnership Risks - Yahoo Finance
Thu, 02 Apr 2026
ClearPoint Neuro (CLPT) director awarded 755 shares as stock compensation - Stock Titan
Thu, 26 Mar 2026
Vanguard amendment shows 0% stake in ClearPoint Neuro (CLPT) after realignment - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |